Vaxxinity, Inc. (OTCPK: VAXX)
Health Care · Biotechnology · US
$0.03
+25400.00% today · +25400.0% 1Y
Vaxxinity, Inc. (OTCPK: VAXX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.23M and employs 57 people.
Over the last twelve months the share price has gained 25400.0%, trading between 0.00 and 0.20.
Tweenvest scores Vaxxinity, Inc. across four factors: quality 25/100. Its strongest factor is quality.
VAXX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.23M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.45
- Dividend yield
- —
- Beta (5Y)
- -74.42
- 52-week high
- $0.20
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 126.75M
- Employees
- 57
- Next earnings
- —
About Vaxxinity, Inc.
Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in Dallas, Texas, is dedicated to advancing novel therapeutic candidates for human application in the United States. Its primary areas of focus are neurological disorders and infectious diseases, particularly those caused by coronaviruses. The company's pipeline features several key programs: UB-311 is a Phase 2 clinical trial candidate targeting toxic aggregated amyloid-beta proteins in the brain, aiming to treat Alzheimer's disease. UB-312, currently in Phase 1 clinical trials, is an investigational therapy designed to address Parkinson's disease and other synucleinopathies, including Lewy body dementia and multiple system atrophy, by targeting detrimental aggregated alpha-synuclein. An anti-tau product candidate is also under development for various neurodegenerative conditions, such as Alzheimer's disease. UB-313 is being developed to alleviate migraines by modulating calcitonin gene-related peptide. An anti-PCSK9 candidate aims to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events by targeting proprotein convertase subtilisin/kexin type 9 serine protease. In the infectious disease segment, UB-612 is a Phase 3 clinical-stage candidate engineered to neutralize the SARS-CoV-2 virus.
- ISIN
- US92244V1044
- Founded
- 2021
- Listed since
- Nov 11, 2021
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.43 | +0.18% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.98 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.44 | +0.22% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.78 | +0.13% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $825.89 | -0.98% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $139.44 | -3.88% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.